{"id":53,"date":"2018-11-30T12:10:31","date_gmt":"2018-11-30T12:10:31","guid":{"rendered":"https:\/\/admin.innaxon.co.uk\/?page_id=53"},"modified":"2018-11-30T12:10:31","modified_gmt":"2018-11-30T12:10:31","slug":"tlr4-cd14-inhibitors-iaxo-synthetic","status":"publish","type":"page","link":"https:\/\/wp.innaxon.co.uk\/?page_id=53","title":{"rendered":"TLR4\/CD14 Inhibitors IAXO (synthetic)"},"content":{"rendered":"<p><b>General Information<\/b><\/p>\n<p><b>IAXO<sup>TM<\/sup> compounds <\/b>are Glycolipids and Benzylammonium Lipids, analogues of lipid A that are designed to act as<br \/>\nToll-like-receptor 4\/TLR4 antagonists that interfere with CD14 and TLR4 ligand binding <i>in vivo<\/i> and <i>in vitro<\/i>.<\/p>\n<p>IAXO&#8217;s represent innovative drug candidates with therapeutic activity in rodent models of (auto\/sterile)<br \/>\n\u200b\u200b\u200b\u200b\u200b\u200b\u200binflammatory diseases, such as neuropathic pain.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>General Information IAXOTM compounds are Glycolipids and Benzylammonium Lipids, analogues of lipid A that are designed to act as Toll-like-receptor 4\/TLR4 antagonists that interfere with CD14 and TLR4 ligand binding in vivo and in vitro. IAXO&#8217;s represent innovative drug candidates with therapeutic activity in rodent models of (auto\/sterile) \u200b\u200b\u200b\u200b\u200b\u200b\u200binflammatory diseases, such as neuropathic pain.<\/p>\n","protected":false},"author":1,"featured_media":54,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-53","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TLR4\/CD14 Inhibitors IAXO (synthetic) -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wp.innaxon.co.uk\/?page_id=53\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TLR4\/CD14 Inhibitors IAXO (synthetic) -\" \/>\n<meta property=\"og:description\" content=\"General Information IAXOTM compounds are Glycolipids and Benzylammonium Lipids, analogues of lipid A that are designed to act as Toll-like-receptor 4\/TLR4 antagonists that interfere with CD14 and TLR4 ligand binding in vivo and in vitro. IAXO&#8217;s represent innovative drug candidates with therapeutic activity in rodent models of (auto\/sterile) \u200b\u200b\u200b\u200b\u200b\u200b\u200binflammatory diseases, such as neuropathic pain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wp.innaxon.co.uk\/?page_id=53\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"375\" \/>\n\t<meta property=\"og:image:height\" content=\"234\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53\",\"url\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53\",\"name\":\"TLR4\/CD14 Inhibitors IAXO (synthetic) -\",\"isPartOf\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53#primaryimage\"},\"image\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg\",\"datePublished\":\"2018-11-30T12:10:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wp.innaxon.co.uk\/?page_id=53\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53#primaryimage\",\"url\":\"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg\",\"contentUrl\":\"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg\",\"width\":375,\"height\":234},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=53#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/wp.innaxon.co.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TLR4\/CD14 Inhibitors IAXO (synthetic)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/#website\",\"url\":\"https:\/\/wp.innaxon.co.uk\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wp.innaxon.co.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TLR4\/CD14 Inhibitors IAXO (synthetic) -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wp.innaxon.co.uk\/?page_id=53","og_locale":"en_GB","og_type":"article","og_title":"TLR4\/CD14 Inhibitors IAXO (synthetic) -","og_description":"General Information IAXOTM compounds are Glycolipids and Benzylammonium Lipids, analogues of lipid A that are designed to act as Toll-like-receptor 4\/TLR4 antagonists that interfere with CD14 and TLR4 ligand binding in vivo and in vitro. IAXO&#8217;s represent innovative drug candidates with therapeutic activity in rodent models of (auto\/sterile) \u200b\u200b\u200b\u200b\u200b\u200b\u200binflammatory diseases, such as neuropathic pain.","og_url":"https:\/\/wp.innaxon.co.uk\/?page_id=53","og_image":[{"width":375,"height":234,"url":"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=53","url":"https:\/\/wp.innaxon.co.uk\/?page_id=53","name":"TLR4\/CD14 Inhibitors IAXO (synthetic) -","isPartOf":{"@id":"https:\/\/wp.innaxon.co.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=53#primaryimage"},"image":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=53#primaryimage"},"thumbnailUrl":"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg","datePublished":"2018-11-30T12:10:31+00:00","breadcrumb":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=53#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wp.innaxon.co.uk\/?page_id=53"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=53#primaryimage","url":"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg","contentUrl":"https:\/\/wp.innaxon.co.uk\/wp-content\/uploads\/2018\/11\/iaxo-compoundsekm375x234ekm.jpg","width":375,"height":234},{"@type":"BreadcrumbList","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=53#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/wp.innaxon.co.uk\/"},{"@type":"ListItem","position":2,"name":"TLR4\/CD14 Inhibitors IAXO (synthetic)"}]},{"@type":"WebSite","@id":"https:\/\/wp.innaxon.co.uk\/#website","url":"https:\/\/wp.innaxon.co.uk\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wp.innaxon.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/53","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53"}],"version-history":[{"count":1,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/53\/revisions"}],"predecessor-version":[{"id":56,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/53\/revisions\/56"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/media\/54"}],"wp:attachment":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}